TET2 and acute myeloid leukemia: Second, additional support comes from the observation that none of the responders to ONV+DAC carried TET2 or TP53 mutations (Supplemental Table S5), although both TET2 and TP53 mutations have previously been associated with favorable response to HMA in AML and MDS [43, 44].